Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
At a glance
Conditions
NCT03089827
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Wake Forest Baptist Medical Center
Winston-Salem, North Carolinano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Suzanne Craft, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Amyloid deposition2 years
Studying the initial amyloid deposition in participants as well as their rate of amyloid accumulation over time will help establish whether there is an early therapeutic window for intervention in high risk patients.